|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
-Unofficial Translation- Alternative refund agreement signed between Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. ("GEN") and Social Security Institution of Türkiye ("SGK") for the drug which has "Gasulphase" active substance and named as "NAGLAZYME 1 MG 5 ML 1 FLK." produced by Biomarin International Limited which our company is distributor. Agreement signed for 3 (three) years period starting from 01.04.2024 and contribution of this agreement to the our company's 3 (three) years total sales is expected above EUR 158.000.000 (approximately TL 5.435.000.000 (Five Billion Four Hundred Thirty Five Million Turkish Liras) with updated exchange rates). |
||||||||